Biophan Makes Two Scientific Presentations at Radiological Society of North America (RSNA).

Presentations Focus on Effective Methods for Improving MRI Safety and Related Testing Protocols

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, will make two presentations this week at the Radiological Society of North America (RSNA) in Chicago, Illinois, related to new information on MRI safety of pacemakers and similar devices and MRI safety testing procedures.

In the first presentation, entitled "Assessment of MRI Induced Heating of Cardiac Pacing Leads: Relevance to Target Patient Populations," Biophan will present data showing the effectiveness of one of its solutions in reducing the heating of pacemaker leads in an MRI environment, even in the worst case conditions that a patient may encounter.

The presentation also shows the effect of the lead's position in the MRI tube, which can be affected by either how the lead is physically placed in the patient or the location of the patient within the tube. The closer the lead is to the wall of the MRI machine, the greater the heating effect. Biophan's technical solution, a tiny integrated circuit placed in the electrode of the lead, was effective in reducing the heating regardless of the location within the MRI tube.

The second presentation was accepted as a Hot Topic submission, and is entitled "MR Scanner Transmit Gain as an Indicator for Lead Heating." In this presentation, Biophan will provide new data related to MRI safety testing protocols. Biophan's experiments indicate that a setting associated with the MRI machine called transmit gain, which is not currently controlled in most reported MRI safety and heating test results, is an important control variable and a critical indicator when performing MRI lead heating experiments. Not controlling this variable can account for wide variations in reports of heating by many researchers.

Michael Weiner, CEO of Biophan Technologies, commented on the significance of these findings. "These two presentations demonstrate the effectiveness of Biophan's solutions for reducing MRI induced heating in pacemaker leads and Biophan's leadership role in developing appropriate testing procedures related to MRI safety of medical devices.

"These testing procedures will be critical to defining the path for FDA approval of MRI conditionally safe medical devices, including those which will incorporate our technologies. Defining appropriate control variables and solutions that can perform in worst case, clinically relevant scenarios is essential to making medical devices safe for use with MRI."

Both presentations can be viewed at http://www.biophan.com/RSNApresentations2006.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company licenses its technologies which improve the MRI safety and image compatibility of medical devices to leading device manufacturers. In addition, the Company is helping to commercialize the MYOTECH MYO-VAD[TM], a new, MRI-compatible cardiac recovery system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.